BiotechTube

5-fluorouracil/salicylic acid + Vehicle

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Oct 1, 2014 → Sep 1, 2015

NCT ID
NCT02289768

About 5-fluorouracil/salicylic acid + Vehicle

5-fluorouracil/salicylic acid + Vehicle is a phase 3 stage product being developed by Almirall for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02289768. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02289768Phase 3Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
Investigational Treatment + Active comparatorNovartisPhase 2
52
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
FluorouracilSanofiPhase 1/2
40
fluorouracil cream 0.5%SanofiApproved
84
Imiquimod + DiclofenacViatrisApproved
82
Imiquimod 5 % CreamViatrisPhase 2
49
ImiquimodViatrisPre-clinical
20
Aldara (Imiquimod)ViatrisPhase 3
74
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
80
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80

Other Products from Almirall

TildrakizumabApproved
80
Tiotropium + AclidiniumApproved
80
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved
80
Pidotimod + PlaceboApproved
80
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelApproved
80